Another great announcement. Another product with the potential to be best-in-class.
Some very encouraging comments by AT. The comments certainly would suggest that there is an unmet medical need...which possibly opens up this product to expedited programs through the FDA (whether that happens or not - I guess we will find out).
He also goes to great length to explain the benefits of the longer half-life in imaging. He even asserts that issues with tumour-to-background ratio are not overcome with by the state of the art PET scanners with their increased sensitivity.
I guess we will learn more in the first half of 2025 when the final results from DISCO are released.
- Forums
- ASX - By Stock
- CU6
- Ann: Last patient assessment completed for SARTATE trial
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
4.64%
!
$4.11

Ann: Last patient assessment completed for SARTATE trial, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.11 |
Change
-0.200(4.64%) |
Mkt cap ! $1.329B |
Open | High | Low | Value | Volume |
$4.20 | $4.27 | $4.09 | $7.447M | 1.792M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $4.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.12 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 4.100 |
2 | 498 | 4.090 |
4 | 20302 | 4.080 |
5 | 10307 | 4.050 |
1 | 1000 | 4.040 |
Price($) | Vol. | No. |
---|---|---|
4.120 | 2000 | 1 |
4.170 | 1699 | 1 |
4.190 | 6000 | 1 |
4.200 | 7776 | 2 |
4.210 | 5000 | 1 |
Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online